RecruitingNot ApplicableNCT02795052
Neurologic Stem Cell Treatment Study
Neurologic Bone Marrow Derived Stem Cell Treatment Study
Sponsor
MD Stem Cells
Enrollment
500 participants
Start Date
Jun 1, 2016
Study Type
INTERVENTIONAL
Conditions
Cognitive ImpairmentDementiaTraumatic Brain InjuryNeuropathyStrokeAmyotrophic Lateral SclerosisAlzheimer DiseaseALSNervous System DiseasesLewy Body DiseaseFrontotemporal DementiaProgressive Supranuclear PalsyParkinsonNeurologic DisordersDiabetic NeuropathiesNeurological DisordersNeurodegenerative DiseasesCadasilChronic Traumatic EncephalopathyCerebral InfarctionCerebral IschemiaCerebral StrokeCerebral HemorrhageMulti-System DegenerationMSA - Multiple System AtrophyLewy Body Variant of Alzheimer Disease
Summary
This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1/3 of the nasal passages in order to determine if such a treatment will provide improvement in neurologic function for patients with certain neurologic conditions. http://mdstemcells.com/nest/
Eligibility
Min Age: 18 Years
Inclusion Criteria6
- Have documented functional damage to the central or peripheral nervous system unlikely to improve with present standard of care.
- Be at least 6 months post-onset of the disease.
- If under current medical therapy (pharmacologic or surgical treatment) for the condition be considered stable on that treatment and unlikely to have reversal of the associated neurologic functional damage as a result of the ongoing pharmacologic or surgical treatment.
- In the estimation of Dr. Weiss and the neurologists have the potential for improvement with BMSC treatment and be at minimal risk of any potential harm from the procedure.
- Be over the age of 18 and capable of providing informed consent.
- Be medically stable and able to be medically cleared by their primary care physician or a licensed primary care practitioner for the procedure. Medical clearance means that in the estimation of the primary care practitioner, the patient can reasonably be expected to undergo the procedure without significant medical risk to health.
Exclusion Criteria6
- All patients must be capable of an adequate neurologic examination and evaluation to document the pathology. This will include the ability to cooperate with the exam.
- Patients must be capable and willing to undergo follow up neurologic exams with the sub-investigators or their own neurologists as outlined in the protocol.
- Patients must be capable of providing informed consent.
- In the estimation of Dr. Weiss the BMSC collection and treatment will not present a significant risk of harm to the patient's general health or to their neurologic function. .
- Patients who are not medically stable or who may be at significant risk to their health undergoing the procedure will not be eligible.
- Women of childbearing age must not be pregnant at the time of treatment and should refrain from becoming pregnant for 3 months post treatment.
Interventions
PROCEDUREIntravenous and Intranasal BMSC
Autologous Bone Marrow Derived Stem Cells provided intravenous and intranasal (lower 1/3 of nose)
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT02795052
Related Trials
Novel Augmentation of DAOIB and Antioxidant for Early Dementia
NCT064675391 location
Mind Your Heart-II
NCT054311921 location
Upper Limb Nerve Cryoneurolysis is Non Inferior to the Usual Care and Has Therapeutic Add Value in Dealing With Shoulder Pain and Functional Problems Caused by Spasticity and Motor Impairment
NCT067824641 location
TMS-fNIRS Personalized Dosing
NCT059164171 location
The CONFORM Pivotal Trial
NCT0514779283 locations